Find Clinical Trial

A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in combination with various standard treatments including hormonal and cytotoxic agents

← Back
Study Phase

Phase 1-2

Therapeutic Area


IndicationSolid tumors
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device


Active Substance CodeS064315
Protocol CodeCL1-64315-003
EudraCT Code2019-000998-23

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.